Holdin announced the Company will exhibit two posters at the European Society of Gene and Cell Therapy 2025 Annual Congress, which ...

The library was constructed by generating a variety of AAV capsid variants through the insertion of random peptides at a specific site in the capsid. Specifically, a 7-mer peptide display library ...

Researchers identified immune cells that attacked the neuronal protein C9orf72 in individuals with ALS, spurring new ...

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of AAV production for gene therapies.

Lonza Group AG has broadened its suite of CGT manufacturing solutions with 2 new products: TheraPEAK AmpliCell Cytokines and ...

In this webinar, Stefanie Müthel and Jessica Fiege will discuss how electroporation using the latest technology boosts cell ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

Thermo Fisher Scientific has introduced the Gibco™ Expi293™ PRO Expression System, a transient expression platform designed to increase yields of a broad range of proteins, including those that are ...

Oh, S. and Shin, J. (2025) Nedd4-1 as a Proliferating Factor in Uterine Cervical Carcinogenesis. Open Journal of Obstetrics and Gynecology, 15, 1640-1652. doi: 10.4236/ojog.2025.1510137 .

The non-viral transfection reagents market presents growth opportunities driven by the demand for cost-effective, low-immunogenicity alternatives to viral vectors, particularly for nucleic acid-based ...

Archimed has acquired a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both of which are in the biologic therapeutics sector. Monthey, Switzerland-based ...